Current Positions
Market prices vs AI target prices. Click values to see assumptions.
OncoTech Pharmaceuticals
ONCO
$47.23
Target: $68.00
+$2.15 (4.8%)
Drug / Indication
Preclinical
Phase I
Phase II
Phase III
Approved
rNPV
ONC-101
Prostate Cancer (mCRPC)
Risk-Adj NPV
$2.65B
ONC-205
NSCLC (2L+)
Risk-Adj NPV
$450M
Genomics Therapeutics
GENE
$23.67
Target: $28.00
-$1.34 (5.4%)
Drug / Indication
Preclinical
Phase I
Phase II
Phase III
Approved
rNPV
GT-301
Melanoma (Advanced)
Risk-Adj NPV
$1.8B
2 more positions
Market Intelligence
Upload documents or select sample data to analyze
Choose a document to analyze
Click to select from available demo files
Or browse available demo documents:
📄 ONC-101 Phase 2 Interim
📊 Q3 Business Update
📋 Patent Filing
🎙️ KOL Interview
AI Analysis in Progress
Processing ONC-101 Phase 2 interim readout
Document Analysis
Identified Phase 2 interim data for ONC-101 in mCRPC patients
▸ n=23 patients evaluable for response
▸ 65% confirmed ORR (15/23 patients)
▸ Previous expectation: 45% ORR
Portfolio Impact Assessment
Analyzing implications for OncoTech (ONCO) valuation
▸ ONC-101 represents 67% of company value
▸ Competing with Lynparza, Zytiga in same space
▸ Market size: $22B prostate cancer market
Statistical Validation
Identified potential concerns with interim data
⚠️ Small sample size (n=23) - high variance
⚠️ 87% had prior Lynparza - selected population
⚠️ 2-week washout (typically 4-6 weeks)
⚠️ Interim analysis - not powered for significance
Scenario Generation
Creating investment scenarios based on analysis
📈 Bull case: Data holds up, competitive positioning
📉 Bear case: Statistical noise, reversion likely
🏢 M&A case: Potential takeout target
⚖️ Base case: Modest ORR improvement
AI Analysis Summary:
• Found 65% ORR vs 45% expected
• Flagged small sample (n=23) and selection bias
• Updated ONC-101 valuation from $2.1B to $2.3B
• Raised target price $68 → $72 (+6% target increase)
• Found 65% ORR vs 45% expected
• Flagged small sample (n=23) and selection bias
• Updated ONC-101 valuation from $2.1B to $2.3B
• Raised target price $68 → $72 (+6% target increase)
Investment Scenarios
AI-generated scenarios based on ONC-101 interim data analysis
🚀 Bull Case
+65% from curr. PPS
Price target: $68 → $78
Price target: $68 → $78
65% ORR holds in full dataset. Superior to current SOC, potential for accelerated approval pathway. Market share gains vs Lynparza.
📊 Updated Base
+52%
$68 → $72
$68 → $72
True ORR ~55% after full enrollment. Modest improvement vs SOC, differentiated safety profile enables market access.
⚠️ Skeptical Case
+15%
$68 → $54
$68 → $54
Small sample bias. Full dataset shows 45-50% ORR. Competitive but not differentiated. Limited upside from current levels.
🏢 M&A Scenario
+85%
$68 → $87
$68 → $87
Strong interim data attracts Big Pharma interest. 2.5x revenue multiple based on recent oncology deals. Premium for early-stage asset.